Alzheimer's disease is a devastating neurodegenerative condition that affects the entire family. As psychiatrists and psychologists, we often support these patients and their families throughout this entire disease process. With the recent and controversial FDA approval of aducanumab (Aduhelm™), a new pharmacotherapy for Alzheimer's disease, we can expect to be asked about this drug from our patients and their family.
By listening to this episode, you can earn 1 Psychiatry CME Credits.
Fler avsnitt av Psychiatry & Psychotherapy Podcast
Visa alla avsnitt av Psychiatry & Psychotherapy PodcastPsychiatry & Psychotherapy Podcast med David Puder, M.D. finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
